1. Scrip
  2. >>R&D

Alphabet To AI Connect, What Favors Drug Development At Indian Institutes Of Technology

CAR-T Dream Achieved

 
• By Vibha Ravi

After starring in India’s first CAR-T treatment, the country’s Indian Institutes of Technology, or IITs, are set to expand their drug development footprint. Scrip takes a look at what the Indian equivalents of the Massachusetts Institute of Technology have going for them, including sizeable funding and alumni like Alphabet's CEO.

Building R&D Capability
Indian Institutes Of Technology Are Building R&D Capabilities In Healthcare • Source: Shutterstock

The launch of India’s first indigenous chimeric antigen receptor (CAR)-T cell therapy NexCAR19 (actalycabtagene autoleucel) last month at nearly 10% of the price of similar treatments available in the country was a truly significant moment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

In Brief: Bioxodes To Take Novel Hemorrhagic Stroke Drug Into Registrational Trial

 
• By Sushmita Panda

The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

Bristol’s Growth Plans Take A Hit As Cobenfy Fails As A Schizophrenia Add-On

 
• By Mandy Jackson

Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.

More from Scrip

Roche Moves To Soften Tariff Blow But Admits M&A Dealmaking Could Be Hit

 
• By Andrew McConaghie

Roche believes it can ride out any short-term effects of US tariffs if they are imposed but wants to see reform of US and European pricing to help support the sector.

In Brief: Boehringer Ingelheim, Tessellate Bio Link For Precision Therapies For ALT Tumors

 
• By Sushmita Panda

In its first pharma collaboration, Tessellate Bio has inked a deal potentially worth more than €500m with Boehringer Ingelheim for therapies for ALT tumors.

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.